Gene therapy injection aims to halt vision loss in AMD patients
NCT ID NCT07392255
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a single injection of CTx001 gene therapy into the eye for people with geographic atrophy, a form of advanced age-related macular degeneration that causes vision loss. The trial involves 75 participants and will monitor safety and whether the treatment can slow damage to the retina over two years, with long-term follow-up up to five years.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
CTx001 (gene therapy)
What this could lead to
If successful, this could slow or stop the progression of geographic atrophy, preserving vision in people with age-related macular degeneration.
What could go wrong
This is an early Phase 1/2 trial with only 75 participants, so results may not apply to everyone. Gene therapy via subretinal injection carries risks like inflammation or vision loss.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
Locations
-
Gundersen Health System
RECRUITINGLa Crosse, Wisconsin, 54601, United States
-
Midwest Eye Institute
RECRUITINGCarmel, Indiana, 46290, United States
-
Retina Foundation of the Southwest
RECRUITINGDallas, Texas, 75231, United States
-
Sierra Eye Associates
RECRUITINGReno, Nevada, 89502, United States
-
The Retina Clinic London
RECRUITINGLondon, London, W1G 7LB, United Kingdom